CASC3 and neoplasm: The administration schedule of CFZ is based on the in vivo study by Demo et al. [81] that showed that CFZ was well tolerated when administered for either 2 or 5 consecutive days and the anti-tumor efficacy of CFZ delivered on 2 consecutive days was greater than that of BTZ administered on its usual clinical dosing schedule with 2 days rest after each dose.